Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion ValuationThe Motley Fool • Thursday
Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To BlindnessInvestors Business Daily • Wednesday
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: AnalystBenzinga • Wednesday
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, EisaiInvestors Business Daily • Tuesday
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's DiseasePRNewsWire • Tuesday